25 Sep 2008 | 14:20
Aurobindo Pharma receives final approval from USFDA
Aurobindo Pharma has received final approval from USFDA to manufacture
and market Didanosine Delayed Release (enteric-coated) capsules 125mg,
200mg, 250mg and 400mg.
Aurobindo Pharma receives final approval from USFDA
Aurobindo Pharma has received final approval from USFDA to manufacture
and market Didanosine Delayed Release (enteric-coated) capsules 125mg,
200mg, 250mg and 400mg.
Didanosine
Delayed Release capsules is the generic version of Bristol Myer
Squibb's Videx EC (Didanosine) Delayed-release capsules, 125mg, 200mg,
250mg and 400mg and is indicated for the treatment of HIV-1 infections
in adults. This is Aurobindo's 78th ANDA approval from the USFDA.
The company made this announcement during the trading hours today, 25 September 2008.
0 comments:
Post a Comment